This editorial by Michelle Flowers was published in the Palm Beach Post on April 22, 2019. Flowers is the president of the Oncology Managers of Florida.
Point of View: Healthcare Costs Must Be Addressed, But Drug Importation Is Not The Solution
With out-of-pocket costs rising for patients, policymakers at the state and federal level are focused on finding solutions to lower costs. Unfortunately, the well-intentioned effort has led Florida’s policymakers to support a drug importation proposal that could put Floridians at risk.
In my role as president of the non-profit statewide organization the Oncology Managers of Florida, I am dedicated to the education and support of those working and caring for cancer patients in the community practice setting.
In the past two years, Florida oncologists have been prosecuted in federal courts for purchasing black market and/or counterfeit medications for use in their practice and placing their patients’ lives at risk. Florida has had issues with counterfeit/adulterated medications since the mid-1990s. During that time, oncologists purchased the drug Procrit, used to stimulate the growth of red blood cells for use in patients receiving chemotherapy, from a wholesale distributer to later discover certain lots of the medication had been tampered with prior to reaching the distribution network and posed serious risks to their patients.
The U.S. Food and Drug Administration (FDA) is responsible for ensuring that food, drugs, biological products and medical devices are effective and safe for public consumption. They prohibit any drug from being introduced or delivered into interstate commerce unless approved by the FDA. The supply or distribution chain allows numerous opportunities for drugs to become mishandled or adulterated, whether in the United States or abroad.
Dr. Scott Gottlieb, who recently stepped down as director of the FDA, shared on social media that he has “seen too many cases where intermediaries purporting to import Canadian drugs really source drugs from unreliable parties and counterfeiters. Just because they say a drug is from a physical Canadian pharmacy, too often that’s false advertising.” This sentiment is shared by the U.S. Department of Health and Human Services as well with no secretary ever supporting an importation proposal.
The FDA does not, and cannot, regularly inspect every foreign facility. They don’t have the resources or authority to effectively enforce an international drug importation program. And, we currently do not have a sufficient number of law enforcement officers to inspect and confiscate misbranded/adulterated drugs to prevent black market drugs from entering the U.S., disguised to look identical to those from the manufacturer.
If we rush to resolve our long-standing issues of the rising out-of-pocket costs by importing drugs both from Canada and abroad, we are placing all Floridians at risk. There are a number of other proposals being discussed, such as ensuring the billions of dollars in rebates are seen in direct out-of-pocket costs by the patient at the pharmacy counter.
This is an issue that requires careful scrutiny and collaborative efforts from manufacturers through to the end user – the patient.